In the context of DLBCL treated with R/CHOP, our focus on rituximab-resistant cells is due to the fact that rituximab resistance is specifically associated with immunotherapy failure through CD20 and BCL2 signalling pathways, whereas resistance to the R/CHOP regimen involves more complex, multifactorial mechanisms [63]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.